SCHEMBL20913957

SCHEMBL20913957

COc1cccc2oc(-c3c(C)[nH]c4c(-c5cccc(C)c5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 3/20 0.34
▸ TNKS2 Q9H2K2 3/20 0.34
▸ PARP2 Q9UGN5 2/20 0.34
▸ ENPP1 P22413 1/20 0.34
▸ F2RL3 Q96RI0 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ HPGD P15428 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ MAT2A P31153 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913911 0.93 HPGD (0.35) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20914067 0.93 ARF6 (0.35) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20819069 0.93 TNKS (0.37) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20931264 0.92 TNKS (0.39) TNKSTNKS2PARP2ENPP1F2RL3
SCHEMBL20914030 0.90 PSEN1 (0.35) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20837034 0.90 TNKS (0.39) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20914062 0.89 TNKS (0.39) TNKSTNKS2PARP2ENPP1F2RL3
SCHEMBL20914116 0.89 KDM4E (0.33) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20914037 0.87 TSHR (0.39) TNKSTNKS2PARP2F2RL3MAPT
SCHEMBL20914243 0.87 F2RL3 (0.35) TNKSTNKS2PARP2F2RL3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback